We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-10.00 | -0.50% | 2,002.00 | 2,006.00 | 2,008.00 | 2,024.00 | 1,994.00 | 2,014.00 | 178,227 | 16:35:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 23.12 | 4.44B |
TIDMHIK
RNS Number : 8929Y
Hikma Pharmaceuticals Plc
17 May 2021
Hikma Pharmaceuticals PLC - EIP B and EIP C Vesting
LONDON, 17 May 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 17 May 2019 under the 2014 Executive Incentive Plan ("EIP") Element B and granted on 16 May 2018 under the 2014 EIP Element C. The Element B awards vested two years after grant and the Element C awards vested three years after grant.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Mazen Darwazah 2 Reason for the notification a) Position/status Executive Vice Chairman b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from the vesting of conditional transaction awards on 16 May 2021 under the EIP Element C. All Shares were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 12,042 d) Aggregated information * Volume 12,042 GBP0.00 GBP0.00 * Price Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Riad Mishlawi 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from the vesting of conditional transaction awards on 16 May 2021 under the EIP Element C. All Shares were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 22,601 d) Aggregated information * Volume 22,601 GBP0.00 * Price GBP0.00 * Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Majda Labadi
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Majda Labadi 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from the vesting of conditional transaction awards on 16 May 2021 under the EIP Element C. All Shares were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 15,855 d) Aggregated information * Volume 15,855 GBP0.00 * Price GBP0.00 * Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Bassam Kanaan
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Bassam Kanaan 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from the vesting of conditional transaction awards on 16 May 2021 under the EIP Element C. All Shares were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 25,729 d) Aggregated information * Volume 25,729 GBP0.00 * Price GBP0.00 * Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Khalid Nabilsi 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from the vesting of conditional transaction awards on 16 May 2021 under the EIP Element C. All Shares were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 23,062 d) Aggregated information * Volume 23,062 GBP0.00 * Price GBP0.00 * Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Susan Ringdal
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Susan Ringdal 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code
b) Nature of the Shares acquired from the vesting of conditional transaction awards on 16 May 2021 under the EIP Element C. Shares were sold to cover tax and the remainder were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 7,522 Price(s): GBP23.835 Volume(s): 6,735 d) Aggregated information * Volume 14,257 GBP23.835 * Price GBP160,528.73p * Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Hussein Arkhagha 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from the vesting of conditional transaction awards on 17 May 2021 under the EIP Element B. All Shares were retained. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 11,246 d) Aggregated information * Volume 11,246 GBP0.00 * Price GBP0.00 * Total e) Date of the transaction 17 May 2021 f) Place of the London Stock Exchange (XLON) transaction
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
17 May 2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBSGDUUUBDGBR
(END) Dow Jones Newswires
May 17, 2021 11:00 ET (15:00 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions